Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Brain Bank

UK Life Sciences Strategy - one year on

Genome diagnostic can see if a patient is ‘ageing well’

Test can predict risk of age-related diseases and age of death

- PMLiVE

Amgen and Novartis collaborate on Alzheimer’s research

Will work on the development and commercialisation of BACE inhibitors

Biogen Idec building

Biogen Idec plans phase III Alzheimer’s trial before year-end

And MS drugs drive 2014 sales          

EU flag

Pharma joins European Alzheimer’s research initiative

Lilly and Janssen among participants of dementia-focused IMI project

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

- PMLiVE

Alzheimer’s charity launches £20m trials fund

Aims to fast-track research into dementia treatments

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

Bristol-Myers Squibb (BMS) building

BMS buys Alzheimer’s player iPierian in $725m deal

Takes control of several promising candidates for neurodegenerative diseases

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

G8 sets 2025 target for effective dementia treatment

World leaders pledge more research funding

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links